LDL apheresis improves coronary flow reserve on the left anterior descending artery in patients with familial hypercholesterolemia and chronic ischemic heart disease

de Gennes, 1967, Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis as heroic treatment, Bull Mem Soc Med Hop Paris, 118, 1377 Thompson, 2010, Efficacy criteria and cholesterol targets for LDL apheresis, Atherosclerosis, 208, 317, 10.1016/j.atherosclerosis.2009.06.010 Schwartz, 2013, Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue, J Clin Apher, 28, 145, 10.1002/jca.21276 Schettler, 2012, Current view: indications for extracorporeal lipid apheresis treatment, Clin Res Cardiol Suppl, 7, 15, 10.1007/s11789-012-0046-6 Leebmann, 2013, Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease: prospective observational multicenter study, Circulation, 128, 2567, 10.1161/CIRCULATIONAHA.113.002432 Mabuchi, 1998, Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group, Am J Cardiol, 82, 1489, 10.1016/S0002-9149(98)00692-4 Rosada, 2014, Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?, Artif Organs, 38, 135, 10.1111/aor.12135 Sampietro, 2015, The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience, Atheroscler Suppl, 18, 268, 10.1016/j.atherosclerosissup.2015.02.040 Sampietro, 1997, Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia, Circulation, 96, 1381, 10.1161/01.CIR.96.5.1381 Puntoni, 2011, Myeloperoxidase modulation by LDL apheresis in familial hypercholesterolemia, Lipids Health Dis, 10, 185, 10.1186/1476-511X-10-185 Gould, 1994, Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium, Circulation, 89, 1530, 10.1161/01.CIR.89.4.1530 Treasure, 1995, Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease, N Engl J Med, 332, 481, 10.1056/NEJM199502233320801 Sampietro, 2000, Improvement of myocardial blood flows by single LDL apheresis assessed with PET Mellwig, 1998, Improvement of coronary vasodilatation capacity through single LDL apheresis, Atherosclerosis, 139, 173, 10.1016/S0021-9150(98)00055-0 Vassalli, 1998, Measurement of coronary flow reserve and its role in patient care, Basic Res Cardiol, 93, 339, 10.1007/s003950050102 Hozumi, 1998, Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography, Circulation, 97, 1557, 10.1161/01.CIR.97.16.1557 Caiati, 1999, Contrast-enhanced transthoracic second harmonic echo Doppler with adenosine: a non invasive, rapid and effective method for coronary flow reserve assessment, J Am Coll Cardiol, 34, 122, 10.1016/S0735-1097(99)00164-3 Lee, 2011, Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia, Am J Cardiovasc Drugs, 11, 363, 10.2165/11594970-000000000-00000 Julius, 2013, Lipoprotein apheresis: an update, Clin Lipidol, 8, 693, 10.2217/clp.13.68 Kroon, 2000, The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels, Atherosclerosis, 152, 519, 10.1016/S0021-9150(00)00371-3 Armstrong, 1998, Stress echocardiography: recommendations for performance and interpretation of stress echocardiography. Stress echocardiography task force of the Nomenclature and Standards Committee of the American Society of Echocardiography, J Am Soc Echocardiogr, 11, 97, 10.1016/S0894-7317(98)70132-4 Dal Porto, 2001, Safety, feasibility, and diagnostic accuracy of accelerated high-dose dipyridamole stress echocardiography, Am J Cardiol, 87, 520, 10.1016/S0002-9149(00)01424-7 Cerqueira, 2002, Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association, Circulation, 105, 539, 10.1161/hc0402.102975 Lang, 2005, J Am Soc Echocardiogr, 18, 1440, 10.1016/j.echo.2005.10.005 Rigo, 2008, The additive prognostic value of wall motion abnormalities and coronary flow reserve during dipyridamole stress echo, Eur Heart J, 29, 79, 10.1093/eurheartj/ehm527 Rigo, 2003, Usefulness of coronary flow reserve over regional wall motion when added to dual-imaging dipyridamole echocardiography, Am J Cardiol, 91, 269, 10.1016/S0002-9149(02)03153-3 Picano, 1994, Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group, Lancet, 344, 1190, 10.1016/S0140-6736(94)90508-8 Sicari, 2008, The prognostic value of Doppler echocardiographic-derived coronary flow reserve is not affected by concomitant antiischemic therapy at the time of testing, Am Heart J, 156, 573, 10.1016/j.ahj.2008.04.016 Hoffman, 1984, Maximal coronary flow and the concept of coronary flow reserve, Circulation, 70, 153, 10.1161/01.CIR.70.2.153 Cortigiani, 2014, Prognostic meaning of coronary microvascular disease in type 2 diabetes mellitus: a transthoracic Doppler echocardiographic study, J Am Soc Echocardiogr, 27, 742, 10.1016/j.echo.2014.02.010 Galderisi, 2012, The impact of aging and atherosclerotic risk factors on transthoracic coronary flow reserve in subjects with normal coronary angiography, Cardiovasc Ultrasound, 10, 20, 10.1186/1476-7120-10-20